Ruihua

Ray-Hwa (Suzhou) Biopharmaceutical is a clinical-stage biotechnology company dedicated to the discovery and development of innovative small molecule targeted therapies for oncology and autoimmune diseases. Founded in 2018 and headquartered in Suzhou Industrial Park, the company leverages its proprietary drug discovery platform to develop a pipeline of high-potency inhibitors for difficult-to-treat mutations. Its lead candidate, RH001, is a next-generation inhibitor targeting EGFR and HER2 exon 20 insertion mutations, currently undergoing Phase 1/2 clinical trials for non-small cell lung cancer. Ray-Hwa's broader pipeline includes selective inhibitors for RET, BTK, and KRAS, aimed at providing precision medicine solutions for patients with limited treatment options. The company is supported by prominent venture capital firms and focuses on overcoming resistance mechanisms in cancer therapy.